Company registration number 08953814 (England and Wales)
MARKETING MEDICINES OTC LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 30 SEPTEMBER 2026
PAGES FOR FILING WITH REGISTRAR
MARKETING MEDICINES OTC LTD
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 4
MARKETING MEDICINES OTC LTD (REGISTERED NUMBER: 08953814)
BALANCE SHEET
AS AT
30 SEPTEMBER 2026
30 September 2026
- 1 -
30 September 2026
30 April 2025
Notes
£
£
£
£
Fixed assets
Tangible assets
3
140
187
Current assets
Debtors
4
19,297
Cash at bank and in hand
211,853
148,878
211,853
168,175
Creditors: amounts falling due within one year
5
(31,347)
(34,805)
Net current assets
180,506
133,370
Net assets
180,646
133,557
Capital and reserves
Called up share capital
6
2
2
Profit and loss reserves
180,644
133,555
Total equity
180,646
133,557
For the financial period ended 30 September 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit of its financial statements for the period in question in accordance with section 476.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true
The financial statements were approved by the board of directors and authorised for issue on 12 October 2026 and are signed on its behalf by:
Mrs A Williamson
Director
MARKETING MEDICINES OTC LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 30 SEPTEMBER 2026
- 2 -
1
Accounting policies
Company information
Marketing Medicines OTC Ltd is a private company limited by shares incorporated in England and Wales. The registered office is 3 James Close, Maidstone Road, Hadlow, Tonbridge, Kent, TN11 0LX.
1.1
Reporting period
The company accounts are presented for a period longer than a year, covering the period from the
1st May 2025 to the 30th September 2026.
1.2
Basis of preparation
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £1.
The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.
1.3
Going concern
Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.
1.4
Turnover
Turnover is recognised at the fair value of consideration received or receivable for the services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates. The following criteria also must be met before turnover is recognised.
Turnover from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
- The amount of turnover can be measured reliably
- It is probable that the company will receive the consideration due under the contract
- the stage of completion of the contract at the end of the reporting period can be measured reliably; and
- the costs incurred and the costs to complete the contract can be measured reliably
1.5
Tangible fixed assets
Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.
MARKETING MEDICINES OTC LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 30 SEPTEMBER 2026
1
Accounting policies
(Continued)
- 3 -
Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Fixtures, fittings & equipment
- 25% on reducing balance
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.
2
Employees
The average monthly number of persons (including directors) employed by the company during the period was:
2026
2025
Number
Number
Total
2
2
3
Tangible fixed assets
Fixtures, fittings & equipment
£
Cost
At 1 May 2025 and 30 September 2026
1,247
Depreciation and impairment
At 1 May 2025
1,060
Depreciation charged in the period
47
At 30 September 2026
1,107
Carrying amount
At 30 September 2026
140
At 30 April 2025
187
4
Debtors
2026
2025
Amounts falling due within one year:
£
£
Trade debtors
19,297
MARKETING MEDICINES OTC LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 30 SEPTEMBER 2026
- 4 -
5
Creditors: amounts falling due within one year
2026
2025
£
£
Trade creditors
1,352
Taxation and social security
25,421
28,953
Other creditors
5,926
4,500
31,347
34,805
6
Called up share capital
2026
2025
2026
2025
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary of £1 each
1
1
1
1
Ordinary A of £1 each
1
1
1
1
2
2
2
2